MAPT and Alzheimer disease: BACE1 and Tau were found to be decreased in the APP/PS1 mice after treatment with miR-124 [59], and biopsy samples from sporadic AD patients revealed reduced levels of miR-124 and increased gene and protein expression of BACE1 [8].